The EEF2K Knockout AGS Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line. This model introduces targeted disruption of the EEF2K gene, which encodes eukaryotic elongation factor 2 kinase. The resulting polyclonal population contains a heterogeneous mixture of edited alleles, enabling loss-of-function studies without clonal selection artifacts. Researchers can utilize this knockout model to dissect EEF2K-dependent mechanisms in an epithelial gastric cancer background.
The AGS cell line was established from a human gastric adenocarcinoma and serves as a widely used in vitro model for gastric cancer biology. These epithelial cells retain key features of the tumor of origin, including aberrant signaling pathways that support proliferation and survival. AGS cells are particularly relevant for investigating oncogenic signaling, drug responses, and metabolic adaptations in gastric cancer. The knockout of EEF2K in this context allows direct interrogation of its role in tumor cell physiology.
EEF2K encodes a calcium/calmodulin-dependent kinase that specifically phosphorylates eukaryotic elongation factor 2 (eEF2) at threonine 56, thereby inhibiting translation elongation. This regulatory step integrates nutrient and energy signals through mTOR and AMPK pathways: mTORC1 suppresses EEF2K activity via S6 kinase, while AMPK activates EEF2K under energy stress. Additionally, PKA can modulate EEF2K function. By phosphorylating eEF2, EEF2K reduces global protein synthesis, a critical response during nutrient deprivation, hypoxia, or other stress conditions. The kinase directly interacts with calmodulin and is a central node connecting mTOR signaling, protein translation, and cellular stress pathways.
In gastric adenocarcinoma, EEF2K has been implicated in promoting cancer cell survival under adverse microenvironments, such as metabolic stress and anticancer drug exposure. The AGS EEF2K knockout model thus provides a powerful tool to study how loss of this kinase affects gastric cancer cell growth, stress resilience, and sensitivity to therapies like mTOR inhibitors (e.g., rapamycin). By comparing the polyclonal knockout population to wild-type AGS cells, investigators can assess changes in translational control, autophagy, and apoptotic thresholds that are critical for tumor maintenance.
Typical applications include monitoring eEF2 phosphorylation status via western blotting, measuring protein synthesis rates through puromycin incorporation assays, and evaluating cell proliferation under normal or stressed conditions. Researchers can also screen for small-molecule inhibitors of EEF2K or test combinatorial treatments with agents targeting the mTOR pathway. Metabolic stress survival assays, such as glucose deprivation or hypoxia challenges, further elucidate the knockout phenotype. For additional experimental guidance or custom cell engineering services, please contact Ascent Research.
